Which has higher earnings and valuation, CABA or IFRX?

InflaRx has higher revenue and earnings than Cabaletta Bio. InflaRx is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A InflaRx $30K 3,903.66 -$51.63M -$0.71 N/A

Is CABA or IFRX more profitable?

InflaRx's return on equity of -88.30% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% InflaRx N/A -88.30% -65.77%

Does the media favor CABA or IFRX?

In the previous week, Cabaletta Bio had 5 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Cabaletta Bio's score of 0.37 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, IFRX or ALT?

InflaRx has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 3,903.66 -$51.63M -$0.71 N/A Altimmune $40K 12,689.17 -$88.09M -$0.93 N/A

Is IFRX or ALT more profitable?

InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Altimmune -214,860.98% -42.57% -35.57%

Does the media prefer IFRX or ALT?

In the previous week, Altimmune had 4 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for Altimmune and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Altimmune's score of 0.56 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNA or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% InflaRx N/A -88.30% -65.77%

Does the media favor DNA or IFRX?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. InflaRx's average media sentiment score of 1.79 beat Ginkgo Bioworks' score of 0.83 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ZSQR or IFRX?

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 332.10%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media favor ZSQR or IFRX?

In the previous week, Coeptis Therapeutics had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Coeptis Therapeutics' score of 0.62 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, VALN or IFRX?

InflaRx has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.53 -$130.33M -$1.87 N/A InflaRx $30K 3,903.66 -$51.63M -$0.71 N/A

Is VALN or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to Valneva's net margin of -88.87%. InflaRx's return on equity of -88.30% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% InflaRx N/A -88.30% -65.77%

Does the media refer more to VALN or IFRX?

In the previous week, Valneva and Valneva both had 2 articles in the media. InflaRx's average media sentiment score of 1.79 beat Valneva's score of 0.82 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

InflaRx (IFRX) Competitors

$1.62 -0.04 (-2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 +0.01 (+0.62%)

As of 07:25 PM Eastern

Compare

IFRX vs. CABA, ALT, DNA, ZSQR, and VALN

Should you buy InflaRx stock or one of its competitors? MarketBeat compares InflaRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InflaRx include Cabaletta Bio (CABA), Altimmune (ALT), Ginkgo Bioworks (DNA), Coeptis Therapeutics (ZSQR), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.

How does InflaRx compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Cabaletta Bio has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market.

InflaRx's return on equity of -88.30% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
InflaRx	N/A	-88.30%	-65.77%

InflaRx has higher revenue and earnings than Cabaletta Bio. InflaRx is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A

42.4% of InflaRx shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cabaletta Bio presently has a consensus target price of $15.50, indicating a potential upside of 409.87%. InflaRx has a consensus target price of $7.00, indicating a potential upside of 332.10%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Cabaletta Bio had 5 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Cabaletta Bio's score of 0.37 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

InflaRx beats Cabaletta Bio on 10 of the 14 factors compared between the two stocks.

How does InflaRx compare to Altimmune?

InflaRx (NASDAQ:IFRX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Altimmune had 4 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for Altimmune and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Altimmune's score of 0.56 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Altimmune	-214,860.98%	-42.57%	-35.57%

InflaRx presently has a consensus price target of $7.00, indicating a potential upside of 332.10%. Altimmune has a consensus price target of $16.67, indicating a potential upside of 538.57%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

42.4% of InflaRx shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InflaRx has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A

Summary

InflaRx and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

How does InflaRx compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Ginkgo Bioworks currently has a consensus price target of $8.50, suggesting a potential upside of 6.68%. InflaRx has a consensus price target of $7.00, suggesting a potential upside of 332.10%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
InflaRx	N/A	-88.30%	-65.77%

InflaRx has lower revenue, but higher earnings than Ginkgo Bioworks. InflaRx is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.06	-$312.76M	-$5.36	N/A
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market.

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. InflaRx's average media sentiment score of 1.79 beat Ginkgo Bioworks' score of 0.83 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

InflaRx beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

How does InflaRx compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Coeptis Therapeutics had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Coeptis Therapeutics' score of 0.62 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Coeptis Therapeutics has higher revenue and earnings than InflaRx. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	392.91	-$11.92M	-$2.52	N/A
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A

InflaRx has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. InflaRx's return on equity of -88.30% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
InflaRx	N/A	-88.30%	-65.77%

Coeptis Therapeutics has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 332.10%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

InflaRx beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks.

How does InflaRx compare to Valneva?

Valneva (NASDAQ:VALN) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

InflaRx has a net margin of 0.00% compared to Valneva's net margin of -88.87%. InflaRx's return on equity of -88.30% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
InflaRx	N/A	-88.30%	-65.77%

Valneva presently has a consensus price target of $11.98, indicating a potential upside of 127.66%. InflaRx has a consensus price target of $7.00, indicating a potential upside of 332.10%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A

In the previous week, Valneva and Valneva both had 2 articles in the media. InflaRx's average media sentiment score of 1.79 beat Valneva's score of 0.82 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

11.4% of Valneva shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valneva has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

Summary

InflaRx beats Valneva on 13 of the 15 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$120.01M	$3.28B	$6.41B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	N/A	18.99	24.46	23.62
Price / Sales	3,903.66	290.48	500.50	105.26
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	2.49	8.00	10.43	6.70
Net Income	-$51.63M	$23.89M	$3.56B	$337.26M
7 Day Performance	-21.36%	-3.49%	-1.39%	-1.41%
1 Month Performance	-37.21%	1.03%	0.86%	1.15%
1 Year Performance	92.86%	34.39%	19.42%	22.61%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.8697 of 5 stars	$1.62 -2.4%	$7.00 +332.1%	+95.3%	$120.01M	$30K	N/A	60	News Coverage
CABA Cabaletta Bio	2.6537 of 5 stars	$3.24 -7.8%	$15.50 +379.1%	+35.9%	$527.48M	N/A	N/A	50
ALT Altimmune	2.0311 of 5 stars	$2.70 -7.7%	$16.67 +518.4%	-55.3%	$524.11M	$36K	N/A	50	News Coverage
DNA Ginkgo Bioworks	0.9951 of 5 stars	$7.98 -11.8%	$8.50 +6.5%	+5.2%	$522.53M	$151.40M	N/A	640	Gap Down
ZSQR Coeptis Therapeutics	0.3942 of 5 stars	$10.05 -7.7%	N/A	+18.1%	$516.87M	$1.36M	N/A	2	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. CABA, ALT, DNA, ZSQR, and VALN

How does InflaRx compare to Cabaletta Bio?

Summary

How does InflaRx compare to Altimmune?

Summary

How does InflaRx compare to Ginkgo Bioworks?

Summary

How does InflaRx compare to Coeptis Therapeutics?

Summary

How does InflaRx compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. CABA, ALT, DNA, ZSQR, and VALN

How does InflaRx compare to Cabaletta Bio?

Which has more volatility & risk, CABA or IFRX?

Is CABA or IFRX more profitable?

Which has higher earnings and valuation, CABA or IFRX?

Do insiders & institutionals have more ownership in CABA or IFRX?

Do analysts rate CABA or IFRX?

Does the media favor CABA or IFRX?

Summary

How does InflaRx compare to Altimmune?

Does the media prefer IFRX or ALT?

Which has more risk and volatility, IFRX or ALT?

Is IFRX or ALT more profitable?

Do analysts rate IFRX or ALT?

Do insiders and institutionals believe in IFRX or ALT?

Which has better earnings and valuation, IFRX or ALT?

Summary

How does InflaRx compare to Ginkgo Bioworks?

Do analysts prefer DNA or IFRX?

Is DNA or IFRX more profitable?

Which has stronger earnings & valuation, DNA or IFRX?

Which has more risk and volatility, DNA or IFRX?

Does the media favor DNA or IFRX?

Do insiders & institutionals hold more shares of DNA or IFRX?

Summary

How does InflaRx compare to Coeptis Therapeutics?

Does the media favor ZSQR or IFRX?

Do insiders and institutionals hold more shares of ZSQR or IFRX?

Which has better earnings and valuation, ZSQR or IFRX?

Is ZSQR or IFRX more profitable?

Which has more risk & volatility, ZSQR or IFRX?

Do analysts prefer ZSQR or IFRX?

Summary

How does InflaRx compare to Valneva?

Is VALN or IFRX more profitable?

Do analysts recommend VALN or IFRX?

Which has preferable valuation & earnings, VALN or IFRX?

Does the media refer more to VALN or IFRX?

Do institutionals & insiders believe in VALN or IFRX?

Which has more volatility and risk, VALN or IFRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools